Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Abstract: Disclosed herein is a novel class of isolated binding molecules including monoclonal antibodies that targets a broadly conserved epitope within the marburgvirus species. Certain aspects provide an effective treatment option for hemorrhagic fever caused by marburgviruses.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a LukAB-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Abstract: This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.

Abstract: Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.

Abstract: This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriolysin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a LukAB-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriolysin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal superantigen (SAg) proteins, or any fragments, variants, or derivatives thereof fused together as a single polypeptide in any order.

Abstract: The disclosure provides non-human primate-derived binding molecules, e.g., antibodies or antigen-binding fragments thereof, that can bind to orthologous epitopes found on two or more filovirus species or strains.

Abstract: This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.

Abstract: Provided herein are methods of incorporating substitutions of specified residues into a filovirus GP in order to increase immunogenicity and/or broaden the cross-reactivity of the protective immune response against other filovirus members. Also provided herein are mutant filovirus GPs comprising such substitutions.

Abstract: This disclosure provides a comprehensive approach to specifically target various immune functions to the site of infection by a variety of fusion proteins that consist of a bacteriocin cell wall targeting domain (CWT) and an immune function mediating component (IFMC). The CWT targets the fusion protein to the bacterial surface leading to accumulation at the site of infection. The IFMC mediates various immune functions such as toxin neutralization or recruitment of immune cells that can clear the bacteria.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.

Abstract: This disclosure provides a method for preventing, treating, or managing a filovirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one binding molecule that includes a binding domain that specifically binds to an orthologous filovirus glycoprotein epitope, wherein the binding domain specifically binds to the epitope on two or more filovirus species or strains.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides delta toxin and phenol-soluble modulin peptides as well as mutants, fragments, variants or derivatives thereof. The disclosure further provides multivalent oligopeptides, fusion proteins comprising two or more staphylococcal proteins, e.g., DT, PSM, alpha hemolysin, leukocidin, superantigen, or any fragments, variants, derivatives, or mutants thereof fused together as a single polypeptide in any order.

Abstract: The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the present disclosure provides methods of inducing an immune response against an alpha-hemolysin-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections.